Villers-lès-Nancy, 7 August 2013 - 18.30 (CET)
PRESS RELEASE
H1 Turnover (at 30 June 2013): up 7.5%
| In millions of euro | 2013 | 2012 | Change |
| Q1 | 29.87 | 26.74 | + 11.7% |
| Q2 | 29.27 | 28.29 | + 3.5% |
| Total H1 | 59.14 | 55.03 | + 7.5% |
The PHARMAGEST Group performed well in the first half of 2013, with revenues up 7.5% year-on-year to €59.14 million and a practically identical breakdown between the first and second quarters. The weaker growth in Q2 is due to an unfavourable basis for comparison.
Business update:
- The Pharmacy France business rose 2.5% during first-half 2013, compared with the same period in 2012. Sales of configurations were up 3.3%, while growth in maintenance remained steady at 5.4%, in line with forecasts. Ancillary products developed by PHARMAGEST INTERACTIVE (licences and services ancillary to the management solution) declined 9.1%, without however eroding profit margins, given their relative weighting in total turnover.
Pharmacy France accounted for 79.1% of overall PHARMAGEST Group turnover in the first half of 2013.
- The Pharmacy business in Belgium and Luxembourg continued its upward trajectory with revenues increasing 15.7% to €1.8 million at 30 June 2013, versus 2012. Growth was driven primarily by sales of configurations (up 33.1%). Recurring revenues are part of the virtuous cycle of PHARMAGEST's business model and have started to generate growth (5.8%). Licence sales declined 10.2% year-on-year, reflecting a base effect due to the signature of a consortium very early in 2012.
As at 30 June 2013, licences accounted for 3.1% of the PHARMAGEST Group's overall turnover.
- The Laboratories business recorded sustained growth in the second quarter, rising 19.6%, bringing the total for H1 2013 to €8.37 million, an increase of 40.3% compared with the same period in 2012. This strong performance was mainly generated by communication services (up 42.9%), as well as conventional high-margin activities (up 15%). Laboratories accounted for 14.2% of overall Group turnover as at 30 June 2013.
- The Care Homes business maintained its strong momentum with revenues rising 16.9% in the first half and by 22.3% in the second quarter alone, compared with the same period in 2012.
This sound performance reflects a 29.6% jump in recurring revenues and an increase of 15.8% in licence sales in the period.
As at 30 June 2013, Care Homes accounted for 3.5% of the PHARMAGEST Group's overal turnover.
- Still in the investment stage, the e-Health business has yet to make any significant contribution to the PHARMAGEST Group's turnover.
Outlook:
After a healthy first half, PHARMAGEST's businesses are set to implement action plans at the start of Q3 to sustain the growth momentum into H2 2013.
In e-Health, the selection of the e-Chronic/e-Nephro project in the French government eHealth 2 call for projects and the visit of Deputy Minister Michèle DELAUNAY mark a major first step in recognising this new business in which the Group will continue to invest.
Financial timetable:
- Publication of half-year results on 27 August 2013
- SFAF results presentation meeting on 10 September 2013
- Publication of Q3 turnover on 14 November 2013
About the PHARMAGEST Group:
The PHARMAGEST Group is the French leader in computer systems for pharmacies, with a 43.5 % share of the market, 9,800 clients and more than 700 employees. Since September 2007, the PHARMAGEST Group has also been present in Northern Europe with a 12 % market share in Belgium and Luxembourg through its subsidiary SABCO.
As a privileged partner to pharmacists for almost 30 years now, the PHARMAGEST Group designs innovative computer solutions for pharmacies and is developing a high potential E-Business E-Media activity intended for laboratories.
The PHARMAGEST Group is also developing previously unpublished software solutions for Retirement Homes, (Care Homes and day centres for the elderly), through its subsidiary MALTA INFORMATIQUE.
The first Logiciel de Gestion à Portail Intégré (Integrated Portal Management Software - LGPI Global Services® ), creator of value for the patient, pharmacist and laboratory, dynamises sales, optimises purchases and enriches advice to the patient. It is also the first permanent impact medium for pharmacies, supplying laboratories with direct communication towards the pharmacist and his patients.
At the heart of the digital revolution that is gradually establishing itself in the daily life of health professionals and patients alike, at the beginning of 2012, the PHARMAGEST Group created an e-Health business, bringing together the subsidiaries DIATELIC (telemedicine and e-health solutions) and DOMEDIC EUROPE (intelligent pill dispenser DO-Pill SecureTM ).
Listed on the NYSE Euronext Paris(TM) - Compartment B
Eligible for the Long-Only Deferred Settlement Service (SRD)
Indices CAC ® SMALL90 and CAC ® All-Tradable by inclusion
ISIN: FR 0000077687 - Reuters: PHA.PA - Bloomberg: - PMGI FP
Find out the latest news from the group at www.pharmagest.com
CONTACTS
Chairman of the Board of Directors:
Thierry CHAPUSOT
Managing Director:
Dominique PAUTRAT
Tel. 03 83 15 90 67 - dominique.pautrat@pharmagest.com
Analysts and Investor Relations:
Administrative and Financial Director: Jean-Yves SAMSON
Tel. 03 83 15 90 67 - jean-yves.samson@pharmagest.com
Press Relations:
FIN'EXTENSO - Isabelle APRILE
Tel. 01 39 97 61 22 - i.aprile@finextenso.fr
